DrugPatentWatch Database Preview
EDARBYCLOR Drug Profile
» See Plans and Pricing
When do Edarbyclor patents expire, and when can generic versions of Edarbyclor launch?
Edarbyclor is a drug marketed by Arbor Pharms Llc and is included in one NDA. There are five patents protecting this drug.
This drug has one hundred and sixteen patent family members in forty-three countries.
The generic ingredient in EDARBYCLOR is azilsartan kamedoxomil; chlorthalidone. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the azilsartan kamedoxomil; chlorthalidone profile page.
US ANDA Litigation and Generic Entry Outlook for Edarbyclor
Edarbyclor was eligible for patent challenges on February 25, 2015.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 4, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for EDARBYCLOR
International Patents: | 116 |
US Patents: | 5 |
Applicants: | 1 |
NDAs: | 1 |
Suppliers / Packagers: | 1 |
Bulk Api Vendors: | 1 |
Clinical Trials: | 1 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for EDARBYCLOR |
DailyMed Link: | EDARBYCLOR at DailyMed |


Generic Entry Opportunity Date for EDARBYCLOR
Generic Entry Date for EDARBYCLOR*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for EDARBYCLOR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Takeda | Phase 3 |
Pharmacology for EDARBYCLOR
Drug Class | Angiotensin 2 Receptor Blocker Thiazide-like Diuretic |
Mechanism of Action | Angiotensin 2 Type 1 Receptor Antagonists |
Physiological Effect | Decreased Blood Pressure Increased Diuresis |
US Patents and Regulatory Information for EDARBYCLOR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Arbor Pharms Llc | EDARBYCLOR | azilsartan kamedoxomil; chlorthalidone | TABLET;ORAL | 202331-001 | Dec 20, 2011 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
Arbor Pharms Llc | EDARBYCLOR | azilsartan kamedoxomil; chlorthalidone | TABLET;ORAL | 202331-002 | Dec 20, 2011 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
Arbor Pharms Llc | EDARBYCLOR | azilsartan kamedoxomil; chlorthalidone | TABLET;ORAL | 202331-001 | Dec 20, 2011 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
Arbor Pharms Llc | EDARBYCLOR | azilsartan kamedoxomil; chlorthalidone | TABLET;ORAL | 202331-002 | Dec 20, 2011 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EDARBYCLOR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Arbor Pharms Llc | EDARBYCLOR | azilsartan kamedoxomil; chlorthalidone | TABLET;ORAL | 202331-001 | Dec 20, 2011 | Start Trial | Start Trial |
Arbor Pharms Llc | EDARBYCLOR | azilsartan kamedoxomil; chlorthalidone | TABLET;ORAL | 202331-002 | Dec 20, 2011 | Start Trial | Start Trial |
Arbor Pharms Llc | EDARBYCLOR | azilsartan kamedoxomil; chlorthalidone | TABLET;ORAL | 202331-001 | Dec 20, 2011 | Start Trial | Start Trial |
Arbor Pharms Llc | EDARBYCLOR | azilsartan kamedoxomil; chlorthalidone | TABLET;ORAL | 202331-002 | Dec 20, 2011 | Start Trial | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for EDARBYCLOR
Country | Patent Number | Estimated Expiration |
---|---|---|
Serbia | 51137 | Start Trial |
Japan | 2010522692 | Start Trial |
Mexico | 2011001150 | Start Trial |
Spain | 2293552 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for EDARBYCLOR
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2119715 | 300802 | Netherlands | Start Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL EN CHLOORTALIDON; NATIONAL REGISTRATION NO/DATE: RVG116387 20151125; FIRST REGISTRATION: CH 6314502 20141028 |
1718641 | C300525 | Netherlands | Start Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCHE AANVAARDBAAR ZOUT, IN HET BIJZONDER HET KALIUMZOUT; REGISTRATION NO/DATE: EU/1/11/734/001-011EU/1/11/735/001-011 2011071207 |
1718641 | 2012/008 | Ireland | Start Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209 |
1718641 | SPC/GB12/028 | United Kingdom | Start Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |